Retroperitoneal fibrosis is seen with which 5HT1 and 5HT2 receptor antagonist: March 2013 (d)
**Core Concept**
Retroperitoneal fibrosis (RPF) is a rare condition characterized by the proliferation of fibrous tissue in the retroperitoneum, leading to the encasement and obstruction of adjacent structures. This condition is often associated with the use of certain medications, particularly those that affect serotonin levels.
**Why the Correct Answer is Right**
The correct answer is a serotonin antagonist that has been linked to the development of RPF. This medication works by blocking the action of serotonin on various receptors, including the 5HT1 and 5HT2 receptors. The blockade of these receptors leads to an increase in the production of fibrogenic cytokines, such as transforming growth factor-beta (TGF-β), which promotes the proliferation of fibrous tissue in the retroperitoneum.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not have a known association with RPF.
* **Option B:** This option is incorrect because it is a different class of medication that is not linked to RPF.
* **Option C:** This option is incorrect because it is a different medication that is not associated with RPF.
**Clinical Pearl / High-Yield Fact**
The use of certain medications, particularly those that affect serotonin levels, can lead to the development of retroperitoneal fibrosis. This is an important consideration for clinicians when prescribing medications that have serotonergic activity.
**Correct Answer:** D. Methysergide.